The FDA approved Eli Lilly’s oral SERD combination therapy Inluriyo for certain patients with second-line metastatic breast cancer. The regimen pairs Lilly’s selective estrogen receptor degrader with additional components used in the new line of therapy, expanding an oral option within an increasingly competitive estrogen-receptor degraders landscape. The authorization adds to Lilly’s broader pivot in endocrine treatment strategies and reflects regulators’ continued focus on defining benefit in specific treatment sequences. Clinicians will now be able to consider the new combination when selecting therapies after first-line treatment. From a pipeline perspective, the approval strengthens Lilly’s position in hormone-driven oncology and underscores the commercial importance of extending SERD utility beyond initial settings as data mature.